工作经历 / Career

• 2024.12 - 今  : betway必威西汉姆联官网 betway唯一官方网站 副教授. （依托黄明东教授课题组）

  2024.12 to date: Professor (Associate), College of Chemistry, Fuzhou University. （Lab Head: Prof. Mingdong Huang）

教育经历 / Education

• 2019.9-2024.12:  清华大学 清华-伯克利深圳学院 精准医学与公共健康专业 博士. (导师：Prof. Vijay K. Pandey，合作导师：Prof. Peter E. Lobie)

  Ph.D., Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Tsinghua University. (Advisor: Prof. Vijay K. Pandey, Co-advisor: Prof. Peter E. Lobie)

• 2015.9-2019.06:  华中科技大学 生命科学与技术学院 生物科学专业 学士.

  Bachelor, Bioscience, College of Life Science and Technology, Huazhong University of Science and Technology.

研究方向 / Research Directions

1. 肿瘤治疗靶点的挖掘与开发.

   Identification and development of oncotherapeutic targets.

2. 肿瘤靶向治疗及分子机制研究.

   Tumor targeted therapy and corresponding molecular mechanisms.

3. 光动力治疗.

   Photodynamic therapy.

4. 血栓疾病的溶栓治疗.

   Thrombolytic therapy and intervention for thromboembolic diseases.

5. 生物医学领域随机课题.

   Any research topic in the field of biomedicine.

代表性论文 / Publications

1. Huang P, Wolde T, Bhardwaj V, Zhang X, and Pandey V. TFF3 and PVRL2 co-targeting identified by multi-omics approach as an effective cancer immunosuppression strategy. Life Sciences. 2024, 357:123113.

2. Huang P, Zhang X, Prabhu JS, and Pandey V. Therapeutic vulnerabilities in triple negative breast cancer: stem-like traits explored within molecular classification. Biomedicine & Pharmacotherapy. 2024, 147:116584.

3. Wolde T, Huang J, Huang P, Pandey V, and Qin PW. Depleted-MLH1 expression predicts prognosis and immunotherapeutic efficacy in uterine corpus endometrial cancer: an in silico approach. BioMedInformatics. 2024, 4:326-346.

4. Zhang X, Wang LQ, Chen S, Huang P, Ma L, Ding H, Basappa B, Zhu T, Lobie PE, and Pandey V. Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma. Communications medicine. 2022, 2:82.

5. Zhang X, Huang P (co-primary), Wang LQ, Chen S, Basappa B, Zhu T, Lobie PE, and Pandey V. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma. Cell death & disease. 2022, 12:558.

国际会议 / Associated international conferences

1. Huang P, Zhang X, Basappa B, Zhu T, Lobie PE, and Pandey V. HDAC1/2 mediates trefoil factor 3 dependent stemness and glucometabolic reprogramming in oestrogen receptor-positive mammary carcinoma. Korea: American Association for Cancer Research-Korean Cancer Association, 2024.

2. Huang J, Zhang X, Huang P, Basappa B, Zhu T, Lobie PE, and Pandey V. Pre-diabetic D-glucose exposure promotes EOC progression and cisplatin resistance: Role of BAD associated pathway and potential therapeutic strategy. Canada: American Association for Cancer Research, 2024.

3. Zhang X, Chen S, Huang P, Pandey V, and Lobie PE. A novel BAD phosphorylation inhibitor combined with EGFR tyrosine kinase inhibitors in EGFR-mutant lung adenocarcinoma treatment. Spain: European Organization for Research and Treatment of Cancer – National Cancer Institute – American Association for Cancer Research, 2022.

专利 / Patents

1. 黄鹏, 维杰·潘迪, 黄晶, 林可, 罗贝·彼特, 张熙, 陈淑. 一种多西霉素浓度梯度依赖性TFF3诱导表达质粒及其应用(2023).

2. 黄晶, 维杰·潘迪, 黄鹏, 郝俊丞, 张熙, 陈淑, 林可, 罗贝·彼特. 一种基于人LDHB基因启动子区的双荧光素酶报告基因载体及其构建方法和应用(2023).

3. 黄晶, 维杰·潘迪, 郝俊丞, 黄鹏, 林可, 张熙, 陈淑, 罗贝·彼特. 一种基于人LDHA基因启动子区的双荧光素酶报告基因载体及其构建方法和应用(2023).

4. 陈淑, 罗贝·彼特, 维杰·潘迪, 张熙, 木兰, 黄鹏, 黄晶, 郝俊丞. 一种稳定表达Luciferase的他莫昔芬耐药细胞株及其构建方法和应用(2022).

5. 陈淑, 罗贝·彼特, 维杰·潘迪, 张熙, 木兰, 黄鹏. 一种肿瘤内分泌药物诱导的休眠或复发细胞株的构建方法(2021).

6. 张熙, 彼得·爱德华·罗比, 维基·库玛·潘迪, 黄鹏, 木兰, 张淑伟. 重组质粒及其应用(2020).

7. 张熙, 彼得·爱德华·罗比, 维基·库玛·潘迪, 黄鹏, 木兰, 张淑伟. 细胞株及其应用(2020).

其他 / Others

欢迎对生物医学领域基础研究感兴趣的同学报考、交流。

联系地址：中国福建省福州市福州地区大学新区学园路2号--betway必威西汉姆联官网国家大学科技园阳光科技楼南613。